Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.64 |
| ▸ | ACACA | Q13085 | 14/20 | 0.64 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182739 | 0.87 | ACACB (0.72) | ACACBACACAKDM2BKDM4E | |
| SCHEMBL6185219 | 0.86 | ACACB (0.56) | ACACBACACAKDM2BKDM4EMEN1 | |
| SCHEMBL976639 | 0.85 | ACACB (0.61) | ACACBACACAKDM2B | |
| SCHEMBL6182596 | 0.84 | ACACB (0.70) | ACACBACACAKDM2B | |
| SCHEMBL6183371 | 0.83 | ACACB (0.67) | ACACBACACAKDM2B | |
| SCHEMBL6183078 | 0.83 | ACACB (0.67) | ACACBACACAKDM2BL3MBTL1GAA | |
| SCHEMBL977837 | 0.82 | ACACB (0.66) | ACACBACACAKDM2BGAA | |
| SCHEMBL2622326 | 0.82 | ACACB (0.66) | ACACBACACAKDM2BGAA | |
| SCHEMBL3465253 | 0.82 | ACACB (0.74) | ACACBACACAKDM2BL3MBTL1GAA | |
| SCHEMBL6183390 | 0.82 | ACACB (0.74) | ACACBACACAKDM2BL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003767-A1 | Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism | NEUERA PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003767-A1 | Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885KDM2B 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.